English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Dr. Ashit Syngle Cardio Rheuma & Healing Touch City Clinc, # 547, Secto16-D, Chandigarh, India Background:Therapeutic approaches used previously reliedon diseasemodifying antirheumatic drugs (DMARDs) that had only partial clinical benefitand were associated with significant toxicity.Spironolactone, an oral aldosterone antagonist, suppresses inflammatory mediators. Clinical efficacy of spironolactone compared with placebo inpatients with active psoriatic arthritis despite treatment with priortraditional DMARDs. Methods: In the 24-week, open label, placebo-controlled, prospective study, patients (n=38) were randomized to placebo and spironolactone (2m/kg/day). Patients on background concurrent DMARDs continued stable doses (methotrexate, leflunomide and/or sulfasalazine). Primary outcome measures were the assessment of disease activity measures i.e. 28-joint disease activity score (DAS28) and diseases activity in psoriatic arthritis (DAPSA) at week 24. The key secondary endpoint was change from baseline in Health Assessment Questionnaire–Disability Index (HAQ-DI) at week 24. Additional efficacy outcome measures at week 24 included improvements in the markers of inflammation (ESR and CRP) and pro-inflammatory cytokines TNF-α, IL-6 and IL-1. Results: At week 24, spironolactone significantly reduced disease activity measure DAS-28 (p<0.001) and DAPSA (p=0.001) compared with placebo. Significant improvements in key secondary measures HAQ-DI (disability index) were evident with spironolactone (p=0.02) versus placebo. After week 24, there was significant reduction in pro-inflammatory cytokines level TNFα, IL-6 (p<0.01) as compared with placebo group. However, there was no significant improvement in IL-1 in both treatment and placebo groups. No change in any biochemical profile was noted after spironolactone treatment. Conclusions: Spironolactone was effective in the treatment of PsA, improving disease activity, physical function and suppressing the level of proinflammatory cytokines. Spironolactone demonstrated an acceptable safety profile and was well tolerated.

Spironolactone in psoriatic arthritis; safety, efficacy and effect on disease activity